Menu
My ERA ERA beitreten

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Suggestions
My Era ERA beitreten
Home | Video pages | Webcast | Genetics and CKD: how common is it? When should we think about it?

Genetics and CKD: how common is it? When should we think about it?

Teilen
https://www.youtube.com/watch?v=5mFPKmBf03Y kopieren